227 related articles for article (PubMed ID: 23576060)
1. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).
Le Dantec C; Alonso R; Fali T; Montero E; Devauchelle V; Saraux A; Pers JO; Renaudineau Y
Immunol Res; 2013 Jul; 56(2-3):341-7. PubMed ID: 23576060
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of CD6 on B-cell subsets from patients with Sjögren's syndrome.
Alonso R; Buors C; Le Dantec C; Hillion S; Pers JO; Saraux A; Montero E; Marianowski R; Loisel S; Devauchelle V; Youinou P; Renaudineau Y
J Autoimmun; 2010 Dec; 35(4):336-41. PubMed ID: 20810246
[TBL] [Abstract][Full Text] [Related]
3. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
Bughani U; Saha A; Kuriakose A; Nair R; Sadashivarao RB; Venkataraman R; Patel S; Deshchougule AT; S SK; Montero E; Pai HV; Palanivelu DV; Melarkode R; Nair P
PLoS One; 2017; 12(7):e0180088. PubMed ID: 28672038
[TBL] [Abstract][Full Text] [Related]
4. The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site.
Whitney GS; Starling GC; Bowen MA; Modrell B; Siadak AW; Aruffo A
J Biol Chem; 1995 Aug; 270(31):18187-90. PubMed ID: 7543097
[TBL] [Abstract][Full Text] [Related]
5. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.
Nair P; Melarkode R; Rajkumar D; Montero E
Clin Exp Immunol; 2010 Oct; 162(1):116-30. PubMed ID: 20726988
[TBL] [Abstract][Full Text] [Related]
6. The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry.
Bowen MA; Bajorath J; Siadak AW; Modrell B; Malacko AR; Marquardt H; Nadler SG; Aruffo A
J Biol Chem; 1996 Jul; 271(29):17390-6. PubMed ID: 8663238
[TBL] [Abstract][Full Text] [Related]
7. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
Loganathan S; Athalye SN; Joshi SR
Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation.
Rambaldi B; Kim HT; Arihara Y; Asano T; Reynolds C; Manter M; Halpern M; Weber A; Koreth J; Cutler C; Gooptu M; Nikiforow S; Ho VT; Antin JH; Romee R; Ampudia J; Ng C; Connelly S; Soiffer RJ; Ritz J
Haematologica; 2022 Nov; 107(11):2617-2629. PubMed ID: 35484649
[TBL] [Abstract][Full Text] [Related]
9. Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction.
Starling GC; Whitney GS; Siadak AW; Llewellyn MB; Bowen MA; Farr AG; Aruffo AA
Eur J Immunol; 1996 Apr; 26(4):738-46. PubMed ID: 8625962
[TBL] [Abstract][Full Text] [Related]
10. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.
Dogra S; Uprety S; Suresh SH
Expert Opin Biol Ther; 2017 Mar; 17(3):395-402. PubMed ID: 28064543
[TBL] [Abstract][Full Text] [Related]
11. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody.
Alonso R; Huerta V; de Leon J; Piedra P; Puchades Y; Guirola O; Chinea G; Montero E
Hybridoma (Larchmt); 2008 Aug; 27(4):291-301. PubMed ID: 18707547
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.
Hernández P; Moreno E; Aira LE; Rodríguez PC
Curr Drug Targets; 2016; 17(6):666-77. PubMed ID: 26844560
[TBL] [Abstract][Full Text] [Related]
13. CD6-ligand interactions: a paradigm for SRCR domain function?
Aruffo A; Bowen MA; Patel DD; Haynes BF; Starling GC; Gebe JA; Bajorath J
Immunol Today; 1997 Oct; 18(10):498-504. PubMed ID: 9357143
[TBL] [Abstract][Full Text] [Related]
14. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.
Aira LE; López-Requena A; Fuentes D; Sánchez L; Pérez T; Urquiza A; Bautista H; Falcón L; Hernández P; Mazorra Z
MAbs; 2014; 6(3):783-93. PubMed ID: 24594862
[TBL] [Abstract][Full Text] [Related]
15. Extracellular isoforms of CD6 generated by alternative splicing regulate targeting of CD6 to the immunological synapse.
Castro MA; Oliveira MI; Nunes RJ; Fabre S; Barbosa R; Peixoto A; Brown MH; Parnes JR; Bismuth G; Moreira A; Rocha B; Carmo AM
J Immunol; 2007 Apr; 178(7):4351-61. PubMed ID: 17371992
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of the CD6 ligand binding domain.
Skonier JE; Bodian DL; Emswiler J; Bowen MA; Aruffo A; Bajorath J
Protein Eng; 1997 Aug; 10(8):943-7. PubMed ID: 9415444
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor.
Ibáñez A; Sarrias MR; Farnós M; Gimferrer I; Serra-Pagès C; Vives J; Lozano F
J Immunol; 2006 Jul; 177(2):1152-9. PubMed ID: 16818773
[TBL] [Abstract][Full Text] [Related]
18. Domain-specific CD6 monoclonal antibodies identify CD6 isoforms generated by alternative-splicing.
Santos RF; Oliveira L; Brown MH; Carmo AM
Immunology; 2019 Aug; 157(4):296-303. PubMed ID: 31162836
[TBL] [Abstract][Full Text] [Related]
19. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.
Rodríguez PC; Prada DM; Moreno E; Aira LE; Molinero C; López AM; Gómez JA; Hernández IM; Martínez JP; Reyes Y; Milera JM; Hernández MV; Torres R; Avila Y; Barrese Y; Viada C; Montero E; Hernández P
Clin Exp Immunol; 2018 Feb; 191(2):229-239. PubMed ID: 28963724
[TBL] [Abstract][Full Text] [Related]
20. Clinical and experimental evidence for targeting CD6 in immune-based disorders.
Consuegra-Fernández M; Lin F; Fox DA; Lozano F
Autoimmun Rev; 2018 May; 17(5):493-503. PubMed ID: 29526637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
